Ferrer Internacional S.A.   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (1959)
Status: No NME R&D (1959)

Organization Overview

First Clinical Trial
2005
NCT00334386
First Marketed Drug
2017
ozenoxacin (xepi)
First NDA Approval
2017
ozenoxacin (xepi)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

FERRER INTERNACIONAL | Ferrer Internacional S.A.